For the fourth straight year, Oracle Health Sciences has been named a “Leader” in the Everest Group Clinical Development Platforms Products PEAK Matrix® Assessment 20201. Oracle Health Sciences maintained its position as the highest positioned vendor in “Vision and Capability” and took the highest position for “Market Impact.”
Everest Group assesses vendors based on their impact in the market (market adoption, value delivered, and portfolio mix) and vision and capability (ability to deliver products successfully, vision and strategy, functionality, flexibility, and ease of deployment, engagement, and commercial model and support). Leaders are companies who are established in supporting mid- and large-size life sciences firms in digital transformation within clinical trials.
Everest Group highlighted that as a “Leader” in the industry, Oracle Health Sciences offers the closest to an end-to-end platform in the current clinical development platform landscape with its Clinical One platform.
“Oracle Health Sciences is honored to be among the Leaders in the Everest Group PEAK Matrix for both our overall impact on the market and the vision and strategy for how technology should support clinical research and pharmacovigilance,” said Henry McNamara, senior vice president and general manager, Oracle Health Sciences. “The life sciences industry is facing unprecedented challenges in the face of the COVID-19 pandemic. This has emphasized the industry need for an approach to clinical trials that is simpler, easier and lower cost, while still supporting the needs of today’s decentralized clinical trials. The PEAK Matrix designation demonstrates that we have delivered on that need with Clinical One and our entire product portfolio to meet tomorrow’s needs today.”
Everest Group identified several Oracle Health Sciences’ strengths that placed them as a Leader, including:
- Strong end-to-end platform capabilities in Clinical One that cover a broad portion of the clinical value chain
- Outstanding modular capabilities in Clinical One, along with a centralized database, which reduces data siloes
- Excellent documentation around new product releases as well as prior releases
“Life sciences clients are beginning to seek solutions to integrate their disparate technologies from across the clinical trial lifecycle. Vendors are, therefore, orchestrating point solutions into integrated end-to-end platforms to bring down total cost of ownership and reduce data siloes for their life sciences pharma clients,” said Nitish Mittal, Vice President, Everest Group. “Oracle Health Sciences’ investments in strengthening its integrated platform vision and user-centric functionality across the clinical development value chain have increased its mindshare among client executives, supporting its positioning as a Leader in Everest Group’s Clinical Development Platforms Products PEAK Matrix Assessment 2020.”
The Everest Group PEAK Matrix® is a proprietary framework for assessing the relative market success and overall capability of service providers based on Performance, Experiences, Ability and Knowledge. Each service provider is comparatively assessed on two dimensions: market success and delivery capabilities. Market success is measured by revenue, number of clients and year-over-year growth. Delivery capability is measured by scale of operations, scope, technology and innovation, delivery footprint and buyer satisfaction. The resulting matrix categorizes service providers as Leaders, Major Contenders, and Aspirants. Companies that demonstrate strong upward movement in successive reports are recognized as Star Performers.
To read the full report, visit here.
